Fourth Quarter & Full Year 2022 Financial & Business Update

Net Product Sales Driven by Strong Demand 4Q22 Net Product Sales grew 26% from 4Q21 YoY Growth 4Q22 480 440 $ in millions $464 NM $432 $428 $18 $17 $16 $383 $86 -9% $369 $11 360 $6 $89 $88 320 $94 $90 $122 +32% 097 $124 $105 240 $93 $100 200 160 120 $238 +35% $202 $219 80 $176 $181 40 4Q21 1Q22 2Q22 3Q22 4Q22 Seagen® Note: Sum of product sales may not equal total net product sales due to rounding; NM = Not meaningful tivdak tisotumab vedotin-tftv for injection 40mg "TUKYSA tucatinib 50 mg 150 mg tablets PADCEV enfortumab vedotin-ejfv Injection for intuin 20mg 30m ADCETRIS brentuximab vedotin for injection 15

View entire presentation